Pasireotide treatment for severe congenital hyperinsulinism due to a homozygous ABCC8 mutation
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases. Current treatment protocols include the first-generation somatostatin analogue octreotide, although pasireotide, a second-generation somatostatin analogue, might be more effective in reducing insulin secretion. Herein we report the first off-label use of pasireotide in a boy with a severe therapy-resistant form of CHI due to a homozygous ABCC8 mutation. After partial pancreatectomy, hyperinsulinism persisted; in an attempt to prevent further surgery, off-label treatment with pasireotide was initiated. Short-acting pasireotide treatment caused high blood glucose level shortly after injection. Long-acting pasireotide treatment resulted in more stable glycemic control. No side effects (e.g., central adrenal insufficiency) were noticed during a 2-month treatment period. Because of recurrent hypoglycemia despite a rather high carbohydrate intake, the boy underwent near-total pancreatectomy at the age of 11 months. In conclusion, pasireotide treatment slightly improved glycemic control without side effects in a boy with severe CHI. However, the effect of pasireotide was not sufficient to prevent near-total pancreatectomy in this case of severe CHI.
Abstract
ABCC8 and KCJN11 mutations cause the most severe diazoxide-resistant forms of congenital hyperinsulinism (CHI). Somatostatin analogues are considered as secondline treatment in diazoxide-unresponsive cases. Current treatment protocols include the first-generation somatostatin analogue octreotide, although pasireotide, a second-generation somatostatin analogue, might be more effective in reducing insulin secretion. Herein we report the first off-label use of pasireotide in a boy with a severe therapy-resistant form of CHI due to a homozygous ABCC8 mutation. After partial pancreatectomy, hyperinsulinism persisted; in an attempt to prevent further surgery, off-label treatment with pasireotide was initiated. Short-acting pasireotide treatment caused high blood glucose level shortly after injection. Long-acting pasireotide treatment resulted in more stable glycemic control. No side effects (e.g., central adrenal insufficiency) were noticed during a 2-month treatment period. Because of recurrent hypoglycemia despite a rather high carbohydrate intake, the boy underwent near-total pancreatectomy at the age of 11 months. In conclusion, pasireotide treatment slightly improved glycemic control without side effects in a boy with severe CHI. However, the effect of pasireotide was not sufficient to prevent near-total pancreatectomy in this case of severe CHI.
참고문헌 (13)
- Gϋemes M, "Hyperinsulinemic hypoglycemia in children and adolescents : recent advances in understanding of pathophysiology and management", Rev Endocr Metab Disord, 21, pp.577~597 (2020)
- Galcheva S, "Diagnosis and management of hyperinsulinaemic hypoglycaemia", Best Pract Res Clin Endocrinol Metab, 32, pp.551~573 (2018)
- Demirbilek H, "Congenital hyperinsulinism : diagnosis and treatment update", J Clin Res Pediatr Endocrinol, 9(Suppl 2), pp.69~87 (2017)
- De Cosio AP, "Current and emerging agents for the treatment of hypoglycemia in patients with congenital hyperinsulinism", Paediatr Drugs, 21, pp.123~136 (2019)
- Banerjee I, "Therapies and outcomes of congenital hyperinsulinism-induced hypoglycaemia", Diabet Med, 36, pp.9~21 (2019)
- Modan-Moses D, "Treatment of congenital hyperinsulinism with lanreotide acetate(Somatuline Autogel)", J Clin Endocrinol Metab, 96, pp.2312~2317 (2011)
- Shah P, "Use of long-acting somatostatin analogue(lanreotide)in an adolescent with diazoxide-responsive congenital hyperinsulinism and its psychological impact", Horm Res Paediatr, 84, pp.355~360 (2015)
- van der Steen I, "A Multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism", Horm Res Paediatr, 89, pp.82~89 (2018)
- Gomes-Porras M, "Somatostatin analogs in clinical practice : a review", Int J Mol Sci, 21, pp.1682~ (2020)
- de Heide LJ, "Treatment of severe postRYGB hyperinsulinemic hypoglycemia with pasireotide : a comparison with octreotide on insulin, glucagon, and GLP-1", Surg Obes Relat Dis, 10, pp.e31~e33 (2014)
- Schwetz V, "Successful medical treatment of adult nesidioblastosis with pasireotide over 3 years: a case report", Medicine (Baltimore), 95, pp.e3272~ (2016)
- Jindal R, "Novel mutation c. 597_598dup in exon 5 of ABCC8 gene causing congenital hyperinsulinism", Diabetes Metab Syndr, 8, pp.45~47 (2014)
- Beltrand J, "Glucose metabolism in 105 children and adolescents after pancreatectomy for congenital hyperinsulinism", Diabetes Care, 35, pp.198~203 (2012)